Dr Douglas Mcneel | Chief Scientific Founder and Head of M.V.I. Scientific Advisory Board
Madison Vaccines Inc.

Dr Douglas Mcneel, Chief Scientific Founder and Head of M.V.I. Scientific Advisory Board, Madison Vaccines Inc.

Dr. McNeel is Professor of Medicine at the University of Wisconsin, Madison. He is a genitourinary medical oncologist with a laboratory and clinical research program that has focused on prostate cancer immunology for over a decade. The long-term goal of Dr. McNeel’s research efforts is to develop effective anti-tumor vaccines as treatments for prostate cancer. His current research efforts seek to identify immunologically recognized proteins of the prostate, characterize these as tumor target antigens, and evaluate anti-tumor genetic vaccines targeting these antigens in appropriate pre-clinical models. Dr. McNeel is specifically evaluating plasmid DNA vaccines encoding these antigens, and is actively translating these findings in early phase human clinical trials. Dr. McNeel is the primary author of multiple issued patents covering the prostatic acid phosphatase and androgen receptor plasmid DNA vaccines, as well as for pending patents on potential biomarkers of patient response to the PAP vaccine. His work provides the underpinning scientific and clinical innovation for MVI. Dr. McNeel has led more than 20 clinical trials and is a frequent podium speaker at national and international conferences on prostate cancer and therapeutic vaccines. Dr. McNeel is Board Certified in Medical Oncology. He holds an M.D. from the University of Chicago Pritzker School of Medicine, a Ph.D. and M.S. in Biochemistry and Molecular Biology from the University of Chicago, and served clinical and postdoctoral fellowships at the University of Washington Seattle.


DC Co-conference Day 2 April 4 @ 3:10

Synergy of DNA Vaccines with checkpoint inhibitors

  • Selection of appropriate vaccine antigens for prostate cancer
  • Updates from ongoing translational trials of DNA vaccines in prostate cancer

back to speakers